Australia's most trusted
source of pharma news
Posted 21 December 2021 AM
There are three CAR-T Cell treatments approved by the TGA and two that are reimbursed by the federal government, yet concerns are raised that Australia's patent system may not be adequate for the new technology.
CAR-T Cell treatments involve isolating a patient's T-cells, modifying them with chimeric antigen receptors to become CAR-T cells, then infusing them into the patient where they attack cancer cells.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.